Investigational drug · Phase 2
INDV-2000
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Opioid Use Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "INDV-2000"
First trial start
2024
Jun 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INDV-2000", any sponsor or status.
Conditions studied
As listed on its trial records.
- Opioid Use Disorder
Approved drugs for the same conditions: Opioid use disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "INDV-2000" as an intervention, largest first.
- Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderPivotal-lookingCompleted
Indivior Inc.Industry
NCT06384157 · 300 participants · Start Jun 10, 2024 · Primary completion Sep 29, 2025
Drug: INDV-2000 · For: Opioid Use Disorder
Sites: Hamilton, Alabama; Phoenix, Arizona; Oceanside, California · 35 sites in all
- INDV-2000 First in HumanCompleted
Indivior Inc.Industry
NCT04413552 · 73 participants · Start Jul 6, 2020 · Primary completion Apr 13, 2021
Drug: INDV-2000; Placebo · For: Opioid Dependence
Sites: Overland Park, Kansas
Indivior Inc.Industry
NCT04976855 · 64 participants · Start Aug 17, 2022 · Primary completion Jul 5, 2023
Drug: INDV-2000; Placebo and 1 more · For: Healthy Volunteer; Opioid-use Disorder
Sites: Baltimore, Maryland; DeSoto, Texas; San Antonio, Texas
Indivior Inc.Industry
NCT05694533 · 20 participants · Start Mar 16, 2023 · Primary completion Apr 6, 2023
Drug: INDV-2000; Midazolam · For: Healthy
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Rocavorexant, a novel, selective orexin-1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder.
Kankam M, Al-Awam R, Shiwach R, et al. · Br J Clin Pharmacol 2026
Also in development for Opioid Use Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- PEX010-Assisted TherapyPEX010Phase 22 trials
Filament Health Corp. · Stimulant Use Disorder, Opioid Use Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.